Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Riccardo Scotto, Antonio Riccardo Buonomo, Stefania De Pascalis, Mariagiovanna Nerilli, Biagio Pinchera, Laura Staiano, Simona Mercinelli, Letizia Cattaneo, Maria Stanzione, Gianfranca Stornaiuolo, Salvatore Martini, Vincenzo Messina, Carmine Coppola, Nicola Coppola & Ivan Gentile. (2021) Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results. Expert Review of Gastroenterology & Hepatology 15:9, pages 1057-1063.
Read now
Read now
Alberto E Maraolo, Riccardo Scotto, Emanuela Zappulo, Biagio Pinchera, Nicola Schiano Moriello, Salatore Nappa, Antonio Riccardo Buonomo & Ivan Gentile. (2020) Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. Expert Review of Anti-infective Therapy 18:3, pages 191-202.
Read now
Read now
Emanuela Zappulo, Riccardo Scotto, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Biagio Pinchera & Ivan Gentile. (2020) Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opinion on Pharmacotherapy 21:3, pages 261-273.
Read now
Read now
Guglielmo Borgia, Riccardo Scotto & Antonio Riccardo Buonomo. (2019) An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy. Expert Opinion on Investigational Drugs 28:5, pages 395-397.
Read now
Read now
Guglielmo Borgia, Alberto Enrico Maraolo, Salvatore Nappa, Ivan Gentile & Antonio Riccardo Buonomo. (2018) NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opinion on Investigational Drugs 27:3, pages 243-250.
Read now
Read now
Articles from other publishers (10)
Lívia Victor, Renata Perez, Flávia Fernandes, Juliana Piedade, Cristiane A. Villela-Nogueira & Gustavo Pereira. (2022) Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort. Medicine 101:35, pages e30097.
Crossref
Crossref
Antonio Riccardo Buonomo, Riccardo Scotto, Carmine Coppola, Biagio Pinchera, Giulio Viceconte, Costanza Maria Rapillo, Laura Staiano, Mariarosaria Saturnino, Ferdinando Scarano, Federica Portunato, Mariantonietta Pisaturo, Stefania De Pascalis, Salvatore Martini, Grazia Tosone, Salvatore Nappa, Nicola Coppola & Ivan Gentile. (2020) Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence. Medicine 99:6, pages e18948.
Crossref
Crossref
Riccardo Scotto, Antonio Riccardo Buonomo, Nicola Schiano Moriello, Alberto Enrico Maraolo, Emanuela Zappulo, Biagio Pinchera, Ivan Gentile & Guglielmo Borgia. (2019) Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. Reviews on Recent Clinical Trials 14:3, pages 173-182.
Crossref
Crossref
Ivan Gentile, Riccardo Scotto, Carmine Coppola, Laura Staiano, Daniela Caterina Amoruso, Teresa De Simone, Federica Portunato, Stefania De Pascalis, Salvatore Martini, Margherita Macera, Giulio Viceconte, Grazia Tosone, Antonio Riccardo Buonomo, Guglielmo Borgia & Nicola Coppola. (2018) Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort). Hepatology International 13:1, pages 66-74.
Crossref
Crossref
Patrice Cacoub, Anne Claire Desbois, Cloe Comarmond & David Saadoun. (2018) Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut 67:11, pages 2025-2034.
Crossref
Crossref
Andrew C. Flick, Hong X. Ding, Carolyn A. Leverett, Sarah J. Fink & Christopher J. O’Donnell. (2018) Synthetic Approaches to New Drugs Approved During 2016. Journal of Medicinal Chemistry 61:16, pages 7004-7031.
Crossref
Crossref
Edward Gane, Catherine Stedman, Kiran Dole, Jin Chen, Charles Daniel Meyers, Brigitte Wiedmann, Jin Zhang, Prakash Raman & Richard A. Colvin. (2016) A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial. ACS Infectious Diseases 3:2, pages 144-151.
Crossref
Crossref
Francesca Romana Ponziani, Francesca Mangiola, Cecilia Binda, Maria Assunta Zocco, Massimo Siciliano, Antonio Grieco, Gian Lodovico Rapaccini, Maurizio Pompili & Antonio Gasbarrini. (2017) Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World Journal of Hepatology 9:7, pages 352.
Crossref
Crossref
Martijn Fenaux, Xiaodong Lin, Fumiaki Yokokawa, Zachary Sweeney, Oliver Saunders, Lili Xie, Siew Pheng Lim, Marianne Uteng, Kyoko Uehara, Robert Warne, Wang Gang, Christopher Jones, Satya Yendluri, Helen Gu, Keith Mansfield, Julie Boisclair, Tycho Heimbach, Alexandre Catoire, Kathryn Bracken, Margaret Weaver, Heinz Moser & Weidong Zhong. (2016)
Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased
In Vivo
Mitochondrial Toxicity Risk
. Antimicrobial Agents and Chemotherapy 60:12, pages 7077-7085.
Crossref
Crossref
Wensheng Yu, Ling Tong, Bin Hu, Bin Zhong, Jinglai Hao, Tao Ji, Shuai Zan, Craig A. Coburn, Oleg Selyutin, Lei Chen, Laura Rokosz, Sony Agrawal, Rong Liu, Stephanie Curry, Patricia McMonagle, Paul Ingravallo, Ernest Asante-Appiah, Shiying Chen & Joseph A. Kozlowski. (2016) Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. Journal of Medicinal Chemistry 59:22, pages 10228-10243.
Crossref
Crossref